KAT BALINGIT: Open Payments
NPI 1538790605 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,736 in 95 payments from 10 companies in 2025. Trend: 2023 $2,219 · 2024 $1,910 · 2025 $2,736
Food & beverage: $2,736
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $589 |
| Alkermes, Inc. | 17 | $481 |
| Neurocrine BioSciences, Inc. | 14 | $352 |
| Vanda Pharmaceuticals Inc. | 6 | $305 |
| Otsuka America Pharmaceutical, Inc. | 12 | $288 |
| E.R. Squibb & Sons, L.L.C. | 11 | $272 |
| Janssen Pharmaceuticals, Inc | 7 | $264 |
| Teva Pharmaceuticals USA, Inc. | 5 | $110 |
| ABBVIE INC. | 3 | $56 |
| Lundbeck LLC | 1 | $19 |
Products named: CAPLYTA, ARISTADA, INGREZZA, COBENFY, HETLIOZ, FANAPT, ABILIFY MAINTENA, LYBALVI.
Industry payments across CA — which companies pay providers there.
